Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simnotrelvir/Ritonavir for Mild-to-Moderate COVID-19
NCT05506176Phase 3Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Simnotrelvir + Ritonavir with Placebo (2 arms). Primary endpoint: Time to sustained recovery of 11 COVID-19 symptoms at Day 29. Started Aug 2022; status: completed.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05506176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506176.